Brain Cancer | Specialty

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

November 23rd 2015

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Dr. Gilbert on Precision Medicine in Glioblastoma

November 23rd 2015

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Optimizing Precision Medicine Approaches in Glioblastoma

November 22nd 2015

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

'Groundbreaking' Global Brain Cancer Trial Planned

November 22nd 2015

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

November 22nd 2015

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM

November 22nd 2015

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Dr. Mrugala on Extending Treatment With Temozolomide in Glioblastoma

November 21st 2015

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM

November 21st 2015

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.

Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression

November 21st 2015

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

November 20th 2015

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

November 20th 2015

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Second-Line Optune Improves Survival in GBM

November 20th 2015

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management

November 20th 2015

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

October 29th 2015

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

FDA Expands Optune's Glioblastoma Multiforme Indication

October 5th 2015

The FDA has approved Optune in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed glioblastoma multiforme following surgery, chemotherapy, and radiation therapy.

Dr. Piccioni on Tumor Profiles of Brain Metastases

September 2nd 2015

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives

August 9th 2015

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.